Related by context. All words. (Click for frequent words.) 82 copies mL 72 IU mL 71 HBV DNA 71 undetectable viral load 70 HCV RNA 67 serum HCV RNA 66 serum HBV DNA 66 HIV RNA 66 IU ml 66 HBV DNA levels 65 undetectable HCV RNA 65 viral load 65 viral loads 65 log# copies mL 64 virologic failure 64 plasma HCV RNA 64 ng dL 63 HBeAg seroconversion 62 undetectable viral loads 62 log# 62 pg ml 62 seroconverted 61 log# reduction 61 viral suppression 61 undetectable virus HCV 61 lopinavir r 61 mg kg dose 61 lopinavir r arm 61 pg mL 60 cells mcL 60 -#.# log# 60 adefovir 60 coinfected 60 cells/mm3 60 ng ml 60 HCV genotype 1 60 NNRTI resistance 59 median CD4 59 mg QD 59 g dL 59 % CI #.#-#.# [003] 59 ug dose 59 LPV r 59 ribavirin therapy 59 virologic response 59 seroconversion 59 PSA nadir 59 μmol L 59 undetectable HBV DNA 59 pmol L 59 peginterferon alfa 2a 59 #mg QD [001] 59 genotype 1b 59 atazanavir ritonavir 59 mcg BID 58 CD4 cell 58 ng mL 58 lamivudine monotherapy 58 sustained virologic response 58 detectable HCV RNA 58 biochemical relapse 58 experienced virologic failure 58 microliter 58 sUA 58 HbA1c levels 58 HBeAg 58 HBeAg positive 58 rapid virologic response 58 median PFS 58 cells uL 58 mg dl 58 peginterferon 58 HBeAg negative patients 58 virologic response EVR 58 #.#ng/ml 58 abacavir lamivudine 58 viremia 58 REYATAZ r arm 58 virologic 58 virological failure 57 mcg albinterferon alfa 2b 57 virological response 57 prior chemotherapy regimens 57 statistical significance p 57 -#.# log# copies mL 57 Peg IFN 57 cEVR 57 cells μL 57 PREZISTA ritonavir 57 mL/min/#.# m 2 57 TDF FTC 57 mcL 57 CD4 counts 57 PEG Interferon alfa 57 PREZISTA r 57 HBsAg 57 genotypic resistance 57 HIV uninfected 57 ertapenem 57 umol L 57 mg dL 57 #mg BID [001] 57 interquartile range 57 mcg kg 57 CCyR 57 lopinavir 57 nmol liter 57 LEXIVA r 56 HBeAg negative 56 evaluable subjects 56 seronegative 56 HCV viral 56 HCV genotype 56 peginterferon alfa 2b 56 CD4 + cell 56 mIU mL 56 severe neutropenia 56 undetectable hepatitis C 56 P = .# 56 preintervention 56 complete cytogenetic response 56 ng dl 56 ABC/3TC 56 HBeAg positive patients 56 undetectable viral 56 achieved ACR# 56 tipranavir ritonavir 56 Viread Emtriva Sustiva 56 neutrophil counts 56 ALT flares 56 mcg mL 56 mg BID 56 ribavirin RBV 56 naïve HCV 56 log# IU mL 56 mg ustekinumab 56 plus ribavirin 56 null responders 56 baseline A1C 56 lamivudine 56 PASI scores 56 sUA levels 56 mmol l 56 p = #.# [004] 56 PegIFN RBV 55 Median survival 55 hemoglobin concentrations 55 pegylated interferon 55 Median PFS 55 HCV infected 55 A1c levels 55 infliximab monotherapy 55 sustained virological response 55 μg ml 55 n = 55 antiretroviral naive 55 mIU ml 55 #.#mg/dL 55 CR nPR 55 ALT normalization 55 NRTI 55 p = 55 p = #.# [002] 55 lamivudine refractory patients 55 nucleoside naive 55 placebo dexamethasone 55 evaluable 55 mIU L 55 clodronate 55 certolizumab 55 PREZISTA rtv 55 RNA copies mL 55 mg TID 55 BCG vaccinated 55 CDAI score 55 % CI #.#-#.# [006] 55 mL/min/#.# m2 55 baseline CD4 55 mg qd 55 plasma uric acid 55 alanine aminotransferase 55 -#.# mg dL [002] 55 serum testosterone 55 chlorambucil 55 achieved sustained virologic 55 mmHg systolic 55 anemia hemoglobin 55 #mg QD [002] 55 pCR 54 μg dose 54 SVR# 54 plus OBT 54 alanine aminotransferase ALT 54 lactate dehydrogenase 54 Index CDAI score 54 #mg BID [003] 54 virologic breakthrough 54 virologic suppression 54 achieve sustained virologic 54 ug mL 54 urate lowering therapy 54 hours postdose 54 REYATAZ r 54 corticosteroid dose 54 APTIVUS r 54 dapagliflozin plus 54 achieved sustained virological 54 chronic HCV genotype 54 mm ³ 54 % CI #.#-#.# [007] 54 HCV RESPOND 2 54 fasting plasma glucose FPG 54 mg d 54 nmol L 54 complete cytogenetic 54 aspartate aminotransferase AST 54 nmol l 54 virologically 54 seroprotection 54 endoscopic remission 54 microg 54 glycated hemoglobin levels 54 #mg/day [001] 54 hepatitis C genotype 54 dosing cohorts 54 comparator arm 54 mg dose 54 timepoint 54 treatment naļve 54 fosamprenavir 54 postintervention 54 ritonavir boosted 54 statistically significant p 54 AZT zidovudine Retrovir 54 antibody titers 54 IFN α 54 mCi m 2 54 3TC lamivudine Epivir 54 RGT arm 54 % Confidence Interval 54 HPV-#/# 54 Baseline characteristics 54 mg RDEA# 53 #mg/dl 53 neutrophil count 53 seropositivity 53 CC genotype 53 achieved PASI 53 peg IFN 53 HbA 1c levels 53 peg interferon 53 mcg dose 53 indinavir 53 free survival PFS 53 aged ≥ 53 relapsed MM 53 aminotransferase elevations greater 53 nevirapine Viramune 53 amoxicillin clavulanate 53 HAART 53 nonresponders 53 treatment naïve genotype 53 Hb A1C 53 ALT elevation 53 pegylated interferon alpha 53 recurrent genital herpes 53 ug kg 53 specific antigen PSA 53 #mmHg [002] 53 adefovir treated 53 entecavir 53 mg/m2 dose 53 mEq L 53 interferon alfa 2a 53 progression TTP 53 TMC# r 53 serum concentrations 53 virologic responses 53 Pegasys plus Copegus 53 4mg/kg 53 μg mL 53 #mg/dL [001] 53 seropositive 53 definite stent thrombosis 53 lymphocytosis 53 Index CDAI 53 Platelet counts 53 treatment naive genotype 53 pegylated interferon peg IFN 53 #.#/#.# mm Hg [003] 53 response CCyR 53 dose cohort 53 mm Hg systolic 53 relapsers 53 elevated ALT 53 CIMZIA TM 53 #mmHg [001] 53 8mg/kg 53 HBV infections 53 CR CRu 53 ACR# response 53 Kaplan Meier analysis 53 NNRTI 53 plus methotrexate 53 achieve sustained virological 53 d4T 53 μg doses 53 prior relapsers 53 leukopenia 53 posttreatment 53 antiretroviral naïve 53 antibody titer 53 % CI #.#-#.# [008] 53 NRTI resistance 53 biochemical recurrence 53 HbA1c 53 creatinine clearance 53 mg Lucentis 53 telaprevir dosed 53 X ULN 53 VELCADE melphalan 52 undergone splenectomy 52 PREZISTA r arm 52 mg/m2 52 serum urate levels 52 lumbar spine BMD 52 stage IIIb IV 52 enfuvirtide 52 microbiologically evaluable 52 BARACLUDE ® 52 cGy 52 dose cohorts 52 XIENCE V PROMUS Stent 52 MADRS score 52 mcg QD 52 CrCl 52 #mg BID [002] 52 serum ALT 52 placebo PBO 52 baseline HbA1c 52 darunavir ritonavir 52 pT3 52 oxycodone CR 52 K#N 52 elevated transaminases 52 prospectively defined 52 annualized relapse 52 EDSS scores 52 CIN3 52 placebo 52 tPSA 52 tenofovir emtricitabine 52 anthracycline taxane 52 tipranavir r 52 advanced adenoma 52 Viral load 52 amprenavir 52 diuretic chlorthalidone 52 rheumatoid factor 52 SHBG levels 52 metformin monotherapy 52 NRTIs 52 mg subcutaneously 52 #mg/m# [001] 52 euthyroid 52 plasma viremia 52 QTcF 52 sd = 52 mmHg diastolic 52 plus dexamethasone 52 mU L 52 aminotransferase levels 52 Virologic 52 serum urate 52 nelfinavir 52 p = .# [002] 52 HIV seronegative 52 Crohn Disease Activity 52 mmHg 52 nadolol 52 lopinavir ritonavir Kaletra 52 % CI #.#-#.# [002] 52 tipranavir 52 peginterferon alfa 52 HOMA IR 52 g dl 52 nanomolar 52 evaluable patients 52 M#V mutation 52 NRTI backbone 52 mRCC 52 chronic HCV infection 52 hemoglobin A1c levels 52 recurrent VTE 52 postmenopausal osteoporotic women 52 asymptomatic carotid stenosis 52 Kaplan Meier method 52 ≥ 52 cervical intraepithelial neoplasia 52 low dose cytarabine 52 nadir CD4 cell 52 confidence interval CI 51 μg L 51 null responder HCV 51 anti HBs 51 β blocker 51 LAB GHRH 51 μg dL 51 baseline LDH 51 FluCAM 51 microgram kg 51 MMSE score 51 cART 51 refractory NSCLC 51 apremilast 51 darunavir r 51 univariate analysis 51 kg/m2 51 CK # plasma concentrations 51 alfa 2a 51 microlitre 51 HCV Genotype 51 LVEF 51 administered subcutaneously 51 placebo p = 51 mm Hg 51 aspartate aminotransferase 51 overt hypothyroidism 51 HbA 1c 51 OADs 51 serum phosphate 51 fasting triglyceride levels 51 rapid virological response 51 mU liter 51 DAS# [002] 51 serum prostate 51 serum phosphorus 51 nonsignificant difference 51 heavily pretreated 51 raltegravir 51 μg kg 51 NHANES III 51 receiving VICTRELIS 51 hematologic toxicity 51 mcg Albuferon 51 ml kg 51 EDSS score 51 CRp 51 ug ml 51 hypogonadal 51 5-FU/LV 51 A1C levels 51 timepoints 51 efavirenz EFV 51 Solid Tumors criteria 51 ddI 51 3mg/kg 51 q#h 51 Kaplan Meier 51 parasitaemia 51 Median progression 51 receiving APTIVUS r 51 antibody responses 51 e antigen HBeAg 51 CI #.#-#.# [001] 51 ritonavir boosted atazanavir 51 hypokalemia 51 mcg doses 51 virologically suppressed 51 HAART regimens 51 Engerix B 51 mm Hg diastolic 51 doxorubicin docetaxel 51 ® emtricitabine 51 prior nephrectomy 51 q8h 51 protease inhibitor mutations 51 PegIFN 51 daily subcutaneous injections 51 RLAI 51 #mg/kg [002] 51 coinfected patients 51 Kaplan Meier survival 51 platelet counts 51 Hazard Ratio HR 51 IIIa inhibitors 51 RECIST criteria 51 LTBI 51 incontinence episodes 51 FOLFOX4 51 serum retinol 51 cytogenetic response 51 remission CR 51 CsA 51 viremic 51 -#.# ± [002] 51 BLLs 51 virologic failures 51 adjunctive placebo 51 HCV 51 valacyclovir 51 EGFR TKI 51 posttransplant 51 comparator PI r 51 mg BID dose 51 mg/m2/day 51 advanced neoplasia 51 virological suppression 51 imatinib therapy 51 pegylated interferon alfa 2a 51 postvaccination 51 lispro 51 IQR 51 atazanavir 51 advanced adenomas 51 noncarriers 50 eGFR 50 plasma concentrations 50 telbivudine 50 binary restenosis 50 plus prednisone 50 mcg kg REBETOL 50 aciclovir 50 vicriviroc 50 serum IGF 50 highest tertile 50 TEAEs 50 p = NS 50 ribavirin 50 cubic millimeter 50 mg eq 50 UGT#A# * 50 CD4 count 50 naive HCV 50 thyroglobulin 50 pegylated interferon alfa 2b 50 piperacillin tazobactam 50 baseline Hb 50 creatinine ratio 50 oral antidiabetic medication 50 ritonavir boosted lopinavir 50 adalimumab 50 receiving prophylactic anticoagulation 50 serum aminotransferase levels 50 #mg/m# [002] 50 normotensive 50 unfractionated heparin 50 Pegasys ® 50 serum potassium 50 HCV SPRINT 50 leukocyte count 50 nodular partial response 50 hsCRP levels 50 cTnT 50 imatinib 50 #mg/day [002] 50 #mg dose [002] 50 caspofungin 50 hip BMD 50 noninferiority 50 placebo p 50 mmol L 50 lymphocyte count 50 plasma folate 50 hypophosphatemia 50 randomized #:# 50 Response Evaluation Criteria 50 μg liter 50 CI -#.# 50 posaconazole 50 KRAS mutant tumors 50 KRAS mutations occur 50 micrograms mL 50 HbA1C 50 morphometric vertebral fractures 50 HI titers 50 #μg [002] 50 saline placebo 50 μmol l 50 virus HCV infection 50 Free Survival PFS 50 microalbumin test 50 hemagglutination inhibition 50 titers 50 COMBIVIR 50 boosted atazanavir 50 MBq 50 subcutaneous enoxaparin 50 HCV genotypes 50 splenectomized patients 50 achieved undetectable HCV 50 pmol liter 50 mL min 50 HGPIN 50 hydroxyvitamin D levels 50 lopinavir ritonavir plus 50 invasive carcinomas 50 #mg/dL [002] 50 NSTE ACS 50 cytogenetic responses 50 REMICADE monotherapy 50 monoinfected 50 mg m² 50 Contrave# 50 laboratory abnormalities 50 infliximab 50 aminotransferases 50 VIRAMUNE 50 mg kg 50 parous women 50 achieved statistical significance 50 urine albumin 50 Kaplan Meier estimate 50 achieving PASI 50 #mg ATC 50 nM 50 nucleoside naive patients 50 sulfadoxine pyrimethamine 50 glycated hemoglobin HbA1c 50 serum uric acid 50 sham injections 50 CCR5 tropic HIV 50 FTC TDF 50 neurologic progression 50 serum clusterin levels 50 #mg q8h 50 dexamethasone Decadron 50 normal ULN 50 â ‰ ¥ 50 confidence interval #.#-#.# 50 unfractionated heparin UFH 50 seropositive patients 50 active comparator 50 mg kg Hematide 50 sero positive 50 Cmax 50 p = #.# [003] 50 PEG IFN 50 oral prednisone 50 plus prednisone prednisolone 50 μg 50 ALND 50 cubic milliliter 49 efavirenz emtricitabine 49 androgen deprivation 49 HbA1C levels 49 receiving INTRON 49 nonobese 49 alemtuzumab treated 49 statin monotherapy 49 univariate 49 darunavir 49 octreotide LAR 49 low dose Iluvien 49 tuberculin skin testing 49 blastic phase 49 Primary endpoints 49 Rapid Virologic Response 49 ARB telmisartan 49 steroid dexamethasone 49 lowest tertile 49 thyrotropin levels 49 NAbs 49 endometrial thickness 49 underwent surgical resection 49 baseline neutrophil counts 49 recurrent atrial fibrillation 49 initiating HUMIRA 49 FOLFIRI alone 49 oral FTY# 49 mg q#h 49 DAS# remission 49 serum potassium levels 49 elevated serum creatinine 49 quetiapine XR 49 IELT 49 #OHD levels 49 Pharmacokinetic parameters 49 ejection fractions 49 Q2W 49 CDAI 49 nonfasting triglyceride levels 49 locoregional disease 49 plus MTX 49 colorectal polyp 49 mg orally 49 TMC# [001] 49 dacarbazine 49 noninferior 49 lactate dehydrogenase LDH 49 adjunctive ABILIFY 49 anagrelide 49 protease inhibitor PI 49 kg m² 49 HBsAg positive 49 HCV antibody 49 preoperative PSA 49 hemoglobin Hb 49 pegylated interferon alfa 49 efavirenz 49 Rapid Virological Response 49 oral rivaroxaban 49 unprotected receptive anal 49 plus medroxyprogesterone acetate 49 nonnucleoside reverse transcriptase inhibitors 49 HLA DR2 49 HIV seroconversion 49 dose dexamethasone 49 #.#/#.# mmHg [001] 49 ULORIC 49 Hb A1c 49 DAS# CRP 49 generalized edema 49 cervical lesions 49 mg simvastatin 49 % CI #.#-#.# [004] 49 mmol L. 49 azoospermia 49 mcg dL 49 genotyped 49 fasting insulin 49 SGPT 49 CK MB 49 x ULN 49 rizatriptan 49 mg doses 49 gout flares 49 aminotransferase ALT 49 hemoglobin A1c HbA1c 49 TPV r 49 mg tid 49 docetaxel chemotherapy 49 transaminase elevations 49 K#R [002] 49 Peginterferon Alfa 2a 49 OGTT 49 CIMZIA TM certolizumab pegol 49 flutamide 49 secondary efficacy endpoint 49 R entecavir 49 EpCAM expression 49 mesalamine granules 49 Expanded Disability Status 49 metastatic malignant melanoma 49 nicardipine 49 iPTH 49 degarelix 49 pyrazinamide 49 concentration Cmax 49 pegIFN 49 partial remissions 49 patients evaluable 49 subtrochanteric 49 spontaneous bowel movements 49 ± SD 49 confidence intervals CIs 49 estimated glomerular filtration 49 systolic dysfunction 49 NNRTIs 49 viraemia 49 IR Cysteamine 49 insulin detemir 49 antigen PSA 49 R# #mg BID 49 aldosterone antagonist 49 IRLS score 49 troponin T 49 viral titer 49 interferon alfa 49 #ng/ml 49 serum creatinine levels 49 placebo fluoxetine 49 serum estradiol 49 severe rotavirus gastroenteritis 49 IPSS 49 interferon alfa 2b 49 abacavir 49 asthma exacerbation 49 TNF antagonist 49 Solid Tumors RECIST 49 bortezomib refractory 49 dalteparin 49 Sustained virologic response 49 #μg [001] 49 vertebral fracture 49 uM 49 zidovudine lamivudine 49 multivariate Cox 49 baseline FEV 49 platelet reactivity 49 sunitinib 49 proteinuria 49 weekly subcutaneous injections 49 peripheral blood mononuclear 49 achieved CCyR 49 Virological 49 daunorubicin 49 oral vancomycin 49 atheroma volume 49 #q# deletion syndrome 49 K ras mutations 49 ACTEMRA TM 49 Flu Cy 48 antiretroviral therapy ART 48 Aptivus ® 48 colorectal adenomas 48 benazepril 48 systemic embolism 48 neurodevelopmental impairment 48 fasting plasma glucose 48 mL sec 48 serum magnesium 48 IFN alfa 48 NNRTI resistant virus 48 lamivudine resistant 48 AZT 3TC 48 serum testosterone levels 48 poor metabolizers 48 glycosylated hemoglobin HbA1c 48 CIMZIA ™ 48 Pred Forte 48 bezafibrate 48 trials RCTs 48 IFN alpha 48 mmol liter 48 bevirimat 48 osteopenic 48 anthracycline containing 48 azathioprine 48 fluvastatin 48 budesonide pMDI 48 titrated glipizide 48 FOLFOX 48 nutlin 3a 48 mcg linaclotide 48 HIV HCV coinfected 48 per milliliter 48 mg FV 48 antithymocyte globulin 48 ALVESCO 48 Mg Uk 48 FOLFOX6 48 albumin excretion 48 mutated K ras 48 histologically confirmed 48 recurrent glioblastoma multiforme 48 HCV replicon 48 Sustained Virologic Response 48 3TC 48 systolic blood pressures 48 femoral neck BMD 48 Partial Responses 48 tolterodine ER 48 plasma glucose 48 nondepressed 48 tamsulosin 48 nondiabetic 48 infliximab therapy 48 nonvertebral fractures 48 interferon ribavirin 48 NPH insulin 48 oral allopurinol 48 HIV coinfected 48 baseline serum creatinine 48 NATRECOR R 48 plasma urate 48 prostate cancer CaP 48 nanograms per 48 oxcarbazepine 48 intravenous bolus 48 Kaplan Meier estimates 48 acute gout flares 48 MCyR 48 Non inferiority 48 TT genotype 48 STELARA ® 48 ancrod 48 invasive aspergillosis 48 mg kg hr 48 KRAS mutations 48 Viread Emtriva 48 N telopeptide 48 events SAEs 48 trimethoprim sulfamethoxazole 48 serum CRP 48 chlamydial infection 48 Zometa hazard 48 precancerous cervical lesions 48 tertile 48 mucosal healing 48 serum vitamin D 48 elevated hsCRP 48 VFEND 48 Circumcised men 48 secondary efficacy endpoints 48 statistically significant p = 48 mCi kg 48 premenopausal 48 serum antibody 48 autoantibody positive 48 nonfatal MI 48 resected pancreatic cancer 48 chronic HBV 48 rilpivirine 48 receiving antiretroviral therapy 48 atorvastatin #mg 48 nucleoside reverse transcriptase inhibitors 48 HER2 expression 48 HBV infection 48 lymphopenia 48 lopinavir ritonavir 48 plasma pharmacokinetics 48 prednisone prednisolone plus 48 trastuzumab Herceptin ® 48 febrile neutropenia 48 nmol 48 metastatic GIST 48 T2 lesions 48 HCV infection 48 metastatic renal cell carcinoma 48 viral kinetics 48 serum lipid levels 48 saquinavir ritonavir 48 q#d 48 antihypertensive medications 48 intracranial hemorrhage ICH 48 macroalbuminuria 48 Tipranavir 48 FOLFOX4 alone 48 DAS# scores 48 Inhibin B 48 CMV infection 48 androgen suppression 48 #ug [001] 48 nondiabetic patients 48 CRu 48 rimonabant #mg 48 tapentadol ER 48 DMARD 48 intact parathyroid hormone 48 heterozygotes 48 fluticasone salmeterol 48 -#.# ± [001] 48 microbiological eradication 48 MMSE scores 48 ALT elevations 48 mg m 48 nucleotide analog 48 adenoma 48 hemagglutination inhibition HAI 48 IgG antibody 48 doxorubicin cyclophosphamide 48 bcr abl 48 initiating HAART 48 neuropathy sensory 48 postoperatively 48 ACR# responses 48 Elitek 48 HIV infected 48 -#.# mg dL [001] 48 oxycodone IR 48 carboplatin paclitaxel 48 serum folate 48 mitoxantrone 48 Rh + 48 RBC folate 48 Circulating tumor cells 48 XELOX 48 acneform rash 48 spontaneous preterm delivery 48 mcg 48 imipenem 48 #Gy 48 nonvaccine serotypes 48 IGFBP 48 patients coinfected 48 cirrhotic 48 ipsilateral stroke 48 alkylating agent 48 PSADT 48 fluconazole 48 TAXUS p value 48 COPEGUS 48 liver histology 48 antiretroviral therapy 48 TRAS 48 tenofovir DF 48 cobicistat 48 serum cortisol 48 dose cytarabine 48 #R #R #R [002] 48 nonadherent 48 urinary N telopeptide 48 Virologic failure 48 Ishak fibrosis score 48 dosing cohort 48 subcutaneous dose 48 crossclamp 48 protease inhibitors PIs